Prescription Risk Analysis of Potential Interaction Between Colchicine and Statins
10.13748/j.cnki.issn1007-7693.20230052
- VernacularTitle:秋水仙碱与他汀类潜在药物相互作用处方风险分析
- Author:
Lili WU
1
;
Zunping WU
2
;
Yannan DING
1
;
Jianwen YANG
1
Author Information
1. Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, China
2. Department of Pharmacy, The Third Affiliated Hospital of Zunyi Medical University/Zunyi First People s Hospital, Zunyi 563099, China
- Publication Type:Clinical Trial
- Keywords:
colchicine , statin , drug interaction
- From:
Chinese Journal of Modern Applied Pharmacy
2023;40(24):3439-3444
- CountryChina
- Language:Chinese
-
Abstract:
Abstract:OBJECTIVE To analyze the prescription of potential drug-drug interactions(pDDIS) between colchicine and statins, carry out risk assessment and formulate preventive measures. METHODS The case and research reports of adverse reactions caused by the interaction between colchicine and statins were retrieved from the databases of CNKI, VIP, Wanfang, PubMed and Elsevier, and the literature was analyzed; all outpatient prescriptions of colchicine combined with statins from January 2020 to October 2022 were extracted through hospital rational drug use software to identify potential drug interactions and grade the severity. RESULTS Twenty two cases of adverse drug reactions caused by drug interaction were retrieved, including 1 case control study and 2 observational cohort studies; the majority of adverse reactions were in the elderly, male were more than female; the time of occurrence was concentrated in 21 d of combined medication, and 3 patients died; high dose, old age, male and liver/kidney dysfunction might increase the risk of this pDDIS; a total of 72 prescriptions of colchicine and statins were collected, including 65 atorvastatin prescriptions, 6 rosuvastatin prescriptions, and 1 simvastatin prescription. The risk levels were all serious; one patient developed myopathy after 4 months of colchicine combined with atorvastatin, and improved after 1 month; seven preventive measures had been formulated by clinical pharmacists. CONCLUSION There is pDDIS in colchicine and statin prescriptions in the Affiliated Hospital of Zunyi Medical University. It is necessary to actively implement preventive measures and strengthen monitoring, especially for elderly men and patients with liver/kidney dysfunction in the early stage of combined use.
